Guideline for Bioequivalence Studies of Generic Products for Topical Use |
Choi, Sun-Ok
(Division of Biopharmaceutics, Department of Pharmacology, National Institute of Toxicological Research, Korea Food and Drug Administration)
Jung, Sung-Hee (Division of Biopharmaceutics, Department of Pharmacology, National Institute of Toxicological Research, Korea Food and Drug Administration) Um, So-Young (Division of Biopharmaceutics, Department of Pharmacology, National Institute of Toxicological Research, Korea Food and Drug Administration) Jung, Seo-Jeong (Division of Biopharmaceutics, Department of Pharmacology, National Institute of Toxicological Research, Korea Food and Drug Administration) Kim, Joo-Il (Division of Biopharmaceutics, Department of Pharmacology, National Institute of Toxicological Research, Korea Food and Drug Administration) Chung, Soo-Youn (Division of Biopharmaceutics, Department of Pharmacology, National Institute of Toxicological Research, Korea Food and Drug Administration) |
1 | 약사관계법령집 (2002) |
2 | 생물학적동등성시험기준, 식품의약품안전청고시 제 2002-60호 (2002. 11. 22) |
3 | Guidance for Industry .: Topical Dermatologic Cortico-steroids: In vivo Bioequivalence, US FDA (1995. 6. 2) |
4 | 局所皮膚適用製劑の後發醫葉品のための生物學的同等性試驗ガイドラィン, 日本 国立医藥品食品街生硏究所 (2003.7.7) |
5 | 局所皮膚適用製劑の後發醫藥品のための生物學的同等性試驗がイドライン(Q&A), 日本国 立医藥品食品街生硏究所 (2003. 7. 7) |
6 | 後發醫藥品の生物學的 同等性試驗 がイドライン,日本国立医藥品食品 街生硏究所 (1997. 12. 22) |
7 | 久住 武ら 日本溫泉気候物理医学会業雜誌, 50(3),121 (1987) |
8 | Draft Guidance for Industry: Topical Dermatological Drug Product NDAs and ANDAs - In VIvo Bioavailability, Bioequivalence, In VItro Release, and Associated Studies, US FDA (1998.6. 18) |
9 | Draft Guidance for Industry on Topical Dermatological Drug Product NDAs and ANDAs - In VIvo Bioavailability, Bioequivalence, In VItro Release and Associated Studies; Withdrawal. Federal Register Vol. 67, No. 96, US FDA (2002. 5. 17) |